نانولیپوزوم ها به عنوان حامل های دارورسان جدید

نوع مقاله: مقاله پژوهشی

نویسندگان

1 دانشیار فارماسیوتیکس، مرکز تحقیقات فناوری نانو، دانشگاه علوم پزشکی جندی شاپور اهواز، ایران.

2 دانشجوی دکتری عمومی داروسازی، مرکز تحقیقات فناوری نانو، دانشگاه علوم پزشکی جندی شاپور اهواز، ایران.

چکیده

نانولیپوزوم ها ساختارهای کلوئیدی متشکل از یک غشای دو لایه هستند. در محلول های آبی گروه های آبگریز فسفولیپید به سمت داخل کره و گروهای آب دوستشان به سمت خارج کره جهت گیری می کنند. در نتیجه یک غشاء کروی کاملا بسته تشکیل شده از دولایه مولکولهای چربی بوجود می آید. امروزه این نانوساختارها به عنوان حامل های رسانش دارو، ژن و همچنین مدلسازی غشاهای سلولی چه در حیوان و چه در انسان مورد استفاده قرار می گیرند. توانایی این نانوساختارها در کپسوله نمودن مقدار زیاد دارو، به حداقل رساندن عوارض جانبی ناخواسته، اثربخشی بالا و سمیت پایین توانسته علاقه محققین را به آن جلب کند. محققین حمل داروهای ضد سرطان توسط این نانوحامل­ها را مورد بررسی قرار داده­اند. نتایج این تحقیقات نشان داده است که با استفاده از نانولیپوزوم­ها، دارورسانی به سلول­های هدف بهبود یافته و اثربخشی داروها افزایش یافته است. در این مقاله مروری سعی شده علاوه بر معرفی اجمالی این نانوساختارها، به روش های متنوع ساخت آنها و همچنین کاربرد آنها به عنوان حامل های دارورسان پرداخته شود.

کلیدواژه‌ها


1-Davies JC, Geddes DM, Alton EW. Prospects for gene therapy in lung disease. Curr Opin  Pharmacol 2001;1(3):272-8.

2-Moghimipour E, Aghel N, Mahmoudabadi AZ, Ramezani Z, Handali S. Preparation and Characterization of Liposomes Containing Essential Oil of Eucalyptus camaldulensis Leaf. Jundishapur J Nat Pharm Prod 2012;7(3):117-22.

3-Gregoriadis G. Liposome Technology. London, UK: CRC Press; 1992. P. 432.

4-Moghimipour E, Handali S. Liposomes as drug delivery systems: properties and applications. Res J Pharma Biol Chem Sci 2013;4(1):169-85.

5-Ruozi B, Belletti D, Tombesi A, Tosi G, Bondioli L, Forni F, et al. AFM, ESEM, TEM and CLSM in liposomal characterization: a comparative study. Int J Nanomedicine 2011;6:557-63.

6-Riaz M. Review article: stability and uses of liposomes. Pak J Pharma Sci 1995;8(2):69-79.

7-Kouchak M, Avadi M, Abbaspour M, Jahangiri A, Kargar Boldaji S. Effect of different molecular weights of chitosan on preparation and characterization of insulin loaded nanoparticles by ion gelation method. Int J Drud Dev Res 2012;4(2):271-7.

8-Zhuang J, Ping Q, Song Y, Qi J, Cui Z. Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes. Int J Nanomedicine 2010;5:407-16.

9-Awasthi VD, Garcia D, Goins BA, Phillips WT. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 2003;253(1-2):121-32.

10- Mozafari MR. Nanoliposomes: Preparation and Analysis.  Liposomes : Methods and Protocols. Clayton, VIC, Australia: Phosphagenics R&D Laboratory; 2009. p. 29-50.

11-Richardson ES, Pitt WG, Woodbury DJ. The role of cavitation in liposome formation. Biophys J 2007;93(12):4100-7.

12-Pupo E, Padróna A, Santana E, Sotolongo J, Quintana D, Dueñasb S, et al. Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization--extrusion technique. J Control Release 2005;104(2):379–96.

13-Lapinski MM, Castro-Forero A, Greiner AJ, Ofoli RY, Blanchard GJ. Comparison of liposomes formed by sonication and extrusion: rotational and translational diffusion of an embedded chromophore. Langmuir 2007;23(23):11677–83.

14-Shibata M, Okamato Y, NotitadaKaji, Tokeshi M, Baba Y. Liposome formation by counter current floes an micro channels. Proceedings of the 12th international conference on miniaturized systems for chemistry and life sciences; October 12-16, 2008; San diego, California, USA. p. 1426-28

15-Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro relese study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine 2010;5:101-8.

16-Meure LA, Foster NR, Dehghani F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech 2008;9(3):798-809.

17-Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Delivery 2011;9:24-35.

18-Lasic DD, Joannic R, Keller BC, Frederik PM, Auvray L. Spontaneous Vesiculation. Adv Colloid Interface Sci 2001;89-90:337-49.

19-Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery system: An updated review. Int J Pharm Investig 2012;2(1):2-11.

20-Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert opin Derug Deliv 2012;9(12):1489-503.

21-Takeuchi H, Sugihara H. [Absorption of calcitonin in oral and pulmonary administration with polymer-coated liposomes]. Yakugaku Zasshi 2010;130(9):1135-42. [In Japanese]

22-Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm 2013;39(11):1599-617.

23-Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12(3):348-60.

24-Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J 2007;9(3):E371-7.

25-Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSci Tech 2010;11(1):241-6.

26-Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol 2010;88(8):901-4.

27-Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G. Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999;51(5):565-76.

28-Camelo S, Lajavardi L, Bochot A, Goldenberg B, Naud MC, Fattal E, et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis 2007;13:2263-74.

29-Ichhpujani P, Katz LJ. Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension. Drug, Healthc Patient Saf 2010;2:73-83.

30-Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009;10(3):808-19.

31-Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond) 2011;25(5):578-86.

32-Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro an in vivo studies. AAPS PharmSciTech 2007;8(1):E1–12.

33-Natarajan JV, Chattopadhyay S, Ang M, Darwitan A, Foo S, Zhen M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One 2011;6(9):e24513.

34-Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomedicine 2010;5:581-91.

35-Azanza-Perea JR, Barberan J. Anfotericina B forma liposomica: un perfil farmacocinetico exclusive. Una historia inacabada. Rev Esp Quimioter 2012;25(1):17-24.

36-Mozafari MR,  Mortazavi SM. Nanoliposomes: From Fundamentals to Recent Developments.  Oxford: Trafford Publishing; 2005

37-Mozafari MR, Khosravi-Darani K. An overview of liposome-derived nanocarrier technologies. Nanomaterials Nanosystems Biomed Appl 2007:113-23.

38-Mufamadi MS, Pillay V, Choonara YE, Du Toit LC, Modi G, Naidoo D, et al. A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv 2011;1:939851.

39-Saula JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92(1-20:49-67.

40-Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 2002;4(2):183-94.

41-Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drugs Delive Rev 2004;56(8):1177-92.

42-Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42(5):439-62.

43-Asai T. Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels. Biol Pharm Bull 2012;35(11):1855-61.

44-Bajelan E, Haeri A, Vali AM, Ostad S, Dadashzadeh S. Co-delivery of doxorubicin and PSC(Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci 2012;15(4):568-82.

45-Nie Y, Ji L, Ding H, Xie L, Li L, He B, et al. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics 2012;2(11):1092-103.

46-Accardo A, Mansi R, Salzano G, Morisco A, Aurilio M, Parisi A, et al. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells. J Drug Target 2012.

47-Ikehara Y, Yamanaka M, Yamaguchi T. Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrat-coated liposomes. J Biomed biotechnol 2010;1:242539.

48-Farivar TN, Najafipour R, Johari P. Nano - drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody. N Am J Med Sci 2012;4(11):582-5.

49-Parmar JJ, Singh DJ, Lohade AA, Hegde DD, Soni PS, Samad A, et al. Inhalational systems for Etoposide liposomes: formulation development and in vitro deposition. Indian J Pharm Sci 2011;73(6):656-62.

50-Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of Melanoma. Pigment Cell Melanoma Res 2009;22(4):388-99.

51-Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, Griffioen AW, Mulder WJ, et al. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis 2010;13(2):161-73.

52-Moghimipour E, Tafaghodi M, Balouchi A, Handali S. Formulation and in vitro evaluation of topical liposomal gel of triamcinolone acetonide. Res J Pharma Biol Chem Sci 2013;4(1):101-7.

53-Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004;15(6):518-29.

54-Mizoue T, Horibe T, Maruyama K, Takizawa T, Iwatsuro M, Kono K, et al. Targetabillity and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immunoliposomes to tumor cells. Int J Pharm 2002;237(1-2):129-37.

55-Negishi Y, Endo-Takahashi Y, Suzuki R, Maruyama K, Aramaki Y. [Development of gene delivery system into skeletal muscles by bubble liposomes and ultrasound]. Yakugaku Zasshi 2010;130(11):1489-96. [In Japanese]

56-Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83(5):761-9.

57-Vinogradov SV. Colloidal microgels in drug delivery applicationsCurr Pharm Des 2006;12(36):4703-12.

58-Auguste DT, Armes SP, Brzezinska KR, Deming TJ, Kohn J, Prud'homme RK. pH-triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes. Biomaterials 2006;27(12):2599-608.

59-Derycke ASL, de Witte PAM. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004;56:17-30.

60- Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg  Med Chem 2005;13(17):5043-54.

61-Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003;8(24):1112-20.

62-Staruch RM, Ganguly M, Tannock IF, Hynynen K, Chopra R. Enhanced drug delivey in rabbit VX2 tumors using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 2012;28(8):776-87.